Abstract:
The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HC1 and mannitol or Amitriptyline HC1 and mannitol.
A. CLASSIFICATION OF SUBJECT MATTER
IPC(8) - A61 P 21/02; A61 K 9/00 (2014.01)
CPC - A61 K 9/2018; A61K 9/0056
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
IPC(8) - A61 P 21/02; A61K 9/00
CPC - A61K 9/2018; A61K 31/136; A61K 9/0056

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
IPC(8) - A61 P 21/02; A61K 9/00
CPC - A61K 9/2018; A61K 31/136; A61K 9/0056; USPC - 424/400; 424/409; 264/330 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Patbase; Google, Google Patent
Search terms used: eutectic cyclobenzaprin amrix flexeril manmitoi sugar alcohol polyl pharmaceutical

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>US 2009/0098200 A1 (Temtsin et al.) 16 April 2009 (16.04.2009), para [0048], [0012], [0186], [0118], [0190H01 94]</td>
<td>1-5</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier application or patent but published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed

  "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  "&" document member of the same patent family

Date of the actual completion of the international search
30 September 2014 (30.09.2014)

Date of mailing of the international search report
3 1 OCT 2014

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer: Lee W. Young
PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774
### Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:  because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 6-22, 30-53  because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

- For all inventions to be examined, the appropriate additional examination fees must be paid.

  Group i. Claims 1-5, drawn to a pharmaceutical composition comprising a eutectic of mannitol and Cyclobenzaprine HCl
  
  Group ii. Claims 23-29, drawn to a pharmaceutical composition comprising a eutectic of mannitol and Amitriptyline HCl.

—see extra sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos. 1-5

**Remark on Protest**

☐ The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☒ No protest accompanied the payment of additional search fees.
The inventions listed as Groups I though II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

**Special Technical Features**
- Group I includes the special technical feature of Cyclobenzaprine HCl, not included in the other groups.
- Group II includes the special technical feature of Amitriptyline HCl, not included in the other groups.

**Common Technical Features:**
The only technical feature shared by Groups I and II that would otherwise unify the groups, is a pharmaceutical composition comprising a eutectic including mannitol. However, this shared technical feature does not represent a contribution over prior art, because the shared technical feature is disclosed by US 2007/0141144 A1 to Roberts et al. (hereinafter Roberts).

Roberts discloses pharmaceutical composition comprising a eutectic including mannitol (para [0083], [0012]).

As the technical feature was known in the art at the time of the invention, this cannot be considered a special technical feature that would otherwise unify the groups.

Therefore, Groups I-II lack unity under PCT Rule 13.

**Continuation of Box No. III – Observations where unity of invention is lacking**

**Note:** Claims 6-22 and 30-53 have been found to be unsearchable under Article 17(2)(b) because of defects under Article 17(2)(a) and therefore have not been included in any claim group.